Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s):  CPHRF

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early-to-late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, Vaniqa and Natroba. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. Its Natroba (spinosad) Topical Suspension is indicated for the topical treatment of head lice and scabies infestations in adult and pediatric patients.


TSX:CPH - Post by User

User Avatar Image
(106)
•••
  • Northforce13X
Comment by Northforce13on Sep 01, 2022 6:20pm
389 Views
Post# 34936811

RE:Ez small fast gain available @2.20

RE:Ez small fast gain available @2.20
Probably EZ quick 10% gain within 1-2 months, buy 2.20, sell > 2.40.


Out @2.60, 18% gain in 1 month on the small fun fun play in my tfsa

No bearing on my primary position, which I've held for > 1 year and continue to hold and is >200 times as big in size.  

SP has been robust of late, even without the NCIB.  Maybe something is cooking M&A wise, or, more likely, some analysts and other investors have warmed up to the stock since the latest quarterly release.

The biggest changes I can think of are the expectation of stabilized U.S. revenues (I expected continued decline, actually still expect some decline), expectation that Canada revenues are going to keep growing + surprise about Quebec and BC big potential for a growth shot if they can get public reimbursement for Epuris.  

The big game changer coming down the pipe is MOB-015.  I feel that product alone could be greater than the sales of all their current products combined.  There is no value attributed to this possibility, while I consider it a "probability" more than a possibility. 

Guess time will tell.  Patience.

GLTA
<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities